https://pharmoniq.com/news/novartis-zolgensma-tumour-reports-fda-investigates PharmoniQ en 2026-11-12T14:00:22.532Z Novartis Reports 9 Tumours in Zolgensma Patients as FDA Investigates Novartis, Zolgensma, gene therapy, FDA, drug safety https://pharmoniq.com/news/beam-risto-cel-sickle-cell-beacon-pivotal-12-month-goal PharmoniQ en 2026-11-12T08:07:24.407Z Beam's Base-Edited Sickle Cell Therapy Meets 12-Month Trial Goal Beam Therapeutics, sickle cell disease, base editing, cell therapy, clinical trials https://pharmoniq.com/news/fda-approves-merck-kgaa-pimicotinib-tgct-joint-tumour PharmoniQ en 2026-11-11T13:59:20.395Z FDA Approves Merck KGaA Tumour Pill After 56% Respond in Trial FDA approval, Merck KGaA, EMD Serono, Abbisko, TGCT https://pharmoniq.com/news/argenx-buys-unnatural-products-peptide-biotech-1-15b PharmoniQ en 2026-11-11T08:04:48.609Z Argenx to Pay $550M Upfront in Up to $1.15B Peptide Biotech Buyout argenx, Unnatural Products, acquisitions, peptides, immunology https://pharmoniq.com/blog/lutathera-copies-two-paths-radioligand-generics PharmoniQ en 2026-11-12T11:06:53.246Z Lutathera's First U.S. Copies: Two Paths to Radioligand Generics radiopharma, Lutathera, generics, 505(b)(2), ANDA